10-Q: Tvardi Q3 2025: IPF Trial Misses Goals, Going Concern Doubt

Tvardi Therapeutics reports Q3 2025 results, revealing the TTI-101 IPF Phase 2 trial did not meet its goals, alongside ongoing net losses and substantial doubt about its ability to continue as a going concern, despite a recent merger.

Summary

• Tvardi Therapeutics, a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended September 30, 2025, following its merger with Cara Therapeutics, Inc. in April 2025.
• The company's lead product candidate, TTI-101, in Phase 2 clinical development for idiopathic pulmonary fibrosis (IPF), did not meet its goals, with preliminary data reported on October 13, 2025.
• Discontinuation rates in the TTI-101 IPF trial were high (56.7% for 400mg arm, 62.1% for 800mg arm) compared to placebo (10.3%), primarily due to gastrointestinal adverse events.
• Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms for FVC change, and the placebo-treated patients' FVC decline was lower than expected compared to historical controls.
• TTI-101 is also in Phase 2 clinical development for hepatocellular carcinoma (HCC), with preliminary topline data expected in the first half of 2026.
• The second product candidate, TTI-109, an oral small molecule STAT3 inhibitor, is in an ongoing Phase 1 trial in healthy volunteers, with topline data expected in the first half of 2026.
• The company incurred net losses of $5.5 million for the three months ended September 30, 2025, and $10.9 million for the nine months ended September 30, 2025.
• As of September 30, 2025, Tvardi had an accumulated deficit of $103.2 million and cash and cash equivalents of $21.4 million, along with $15.0 million in short-term investments.
• Management has concluded that there are conditions raising substantial doubt about the company's ability to continue as a going concern.
• The merger with Cara Therapeutics in April 2025 resulted in Tvardi acquiring approximately $23.9 million in net assets and the conversion of convertible notes into 1,265,757 shares of common stock.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the significant setback of the TTI-101 IPF Phase 2 trial failing to meet its goals, coupled with the explicit 'going concern' doubt expressed by management. While there's progress with TTI-101 HCC and TTI-109, and a cash infusion from the merger, the core clinical failure and liquidity concerns overshadow these positives, indicating substantial challenges ahead.

Positives

• The company completed a merger with Cara Therapeutics in April 2025, acquiring approximately $23.9 million in net assets, bolstering its cash position.
• Net loss for the nine months ended September 30, 2025, decreased to $10.9 million from $16.7 million in the prior year, representing a 34.5% improvement.
• Research and development expenses for the three months ended September 30, 2025, decreased by $1.2 million (24.9%) compared to the prior year, primarily due to the discontinuation of the mBC trial and changes in HCC trial enrollment.
• TTI-109, a new oral STAT3 inhibitor designed for improved tolerability, is progressing with Phase 1 trial topline data expected in the first half of 2026.
• Topline data for the TTI-101 HCC clinical trial is expected in the first half of 2026, offering a potential future catalyst.

Negatives

• The Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals, indicating a significant setback for this product candidate in this indication.
• Discontinuation rates in the TTI-101 IPF trial were very high (56.7% for 400mg arm, 62.1% for 800mg arm) compared to placebo (10.3%), primarily due to gastrointestinal adverse events.
• The company continues to incur significant operating losses, with a net loss of $5.5 million for the quarter and an accumulated deficit of $103.2 million as of September 30, 2025.
• Management has concluded that there are conditions present that raise substantial doubt about the company's ability to continue as a going concern.
• General and administrative expenses increased significantly by 165.0% for the three months and 194.1% for the nine months ended September 30, 2025, primarily due to increased professional fees related to the merger and public company operations.
• The company has no products approved for marketing and sale and has not yet recorded any revenue from product sales since inception.

Risks

• The company has a limited operating history and has not generated any revenue to date, making it difficult to evaluate its prospects and likelihood of success.
• Substantial additional capital is required to fund operations and ongoing clinical trials, and there is no assurance that such funding will be available on acceptable terms, if at all.
• The business is highly dependent on the success of TTI-101 and TTI-109, which require significant additional preclinical and clinical development with uncertain outcomes.
• Clinical trials may reveal significant adverse events or unexpected drug-drug interactions, leading to safety profiles that could delay or prevent regulatory approval.
• Interim and preliminary data from clinical trials may change as more patient data become available or additional analyses are conducted, potentially resulting in material changes to final data.
• Positive results from early preclinical studies and clinical trials are not necessarily predictive of later-stage results, as demonstrated by the TTI-101 IPF trial failure.
• Difficulties in enrolling patients in clinical trials, particularly for rare diseases, could delay or adversely affect clinical development activities.
• The company does not own or in-license any composition of matter patent protection for the TTI-101 molecule, relying instead on method-of-use, manufacturing, and pharmaceutical composition patents, which offer narrower protection.
• Material weaknesses were identified in Legacy Tvardi's internal control over financial reporting, including insufficient finance personnel, inadequate segregation of duties, and inadequate review of financial statements and disclosures, which Tvardi must remediate.
• The market price of the company's common stock is expected to be volatile due to various factors, including clinical trial results and financial performance.
• The company is subject to SEC requirements applicable to reporting shell company business combinations, leading to more stringent reporting, offering limitations, and resale restrictions.
• Unfavorable global economic conditions, including inflation and interest rate fluctuations, could adversely affect the company's business and ability to raise capital.

Future Outlook

The company expects to report preliminary topline data from its Phase 1b/2 HCC clinical trial for TTI-101 in the first half of 2026. Topline data from the Phase 1 trial of TTI-109 in healthy volunteers is also expected in the first half of 2026. The company anticipates continuing to incur significant operating losses for the foreseeable future and will require substantial additional funding to finance operations and complete ongoing and planned clinical trials.

Management Comments

• The Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals.
• We are conducting additional analyses to further understand these results and inform next steps for the IPF program.
• We believe the IPF patient population is less tolerant to gastrointestinal treatment emergent adverse events (TEAEs) than the oncology patient population.
• TTI-109 is designed to rapidly convert to TTI-101 and lessen the exposure of the active drug to the intestinal lining, potentially improving tolerability.

Industry Context

Tvardi Therapeutics operates in the highly competitive clinical-stage biopharmaceutical industry, focusing on novel oral small molecule therapies targeting STAT3 for fibrosis-driven diseases and oncology. The company faces competition from major biopharmaceutical and biotechnology companies with significantly greater financial resources and expertise. The industry is characterized by lengthy, complex, and expensive development processes with uncertain outcomes, high attrition rates, and significant regulatory hurdles. The failure of the TTI-101 IPF trial highlights the inherent risks in drug development, particularly in sensitive patient populations where tolerability can be a major factor.

Corporate Governance

Legal Proceedings

• Between December 20, 2024, and March 19, 2025, Cara received 13 demands and three draft complaints from purported stockholders challenging disclosures in the proxy statement/prospectus related to the merger.
• Two lawsuits were filed on March 5 and March 6, 2025, by purported stockholders of Cara in the Supreme Court of the State of New York, challenging merger disclosures.
• Cara filed supplemental disclosures on March 24, 2025, to moot the disclosure claims.
• On August 15, 2025, the company resolved the fee demand related to these merger proceedings, and the matter is now closed.

Stakeholder Impact

• **Shareholders:** Face significant risk due to the TTI-101 IPF trial failure, ongoing net losses, and the 'going concern' doubt. Potential for dilution from future capital raises. Stock price volatility is expected.
• **Employees:** Stock-based compensation is a significant part of their remuneration. The company's ability to attract and retain highly skilled personnel is crucial for future success.
• **Patients (IPF):** The failure of the TTI-101 IPF trial means this specific treatment path is unlikely to proceed as planned, impacting patients hoping for a new therapy.
• **Patients (HCC):** Awaiting topline data for TTI-101 in HCC in H1 2026, which could be a significant development.
• **Third-Party Contractors (CROs, CDMOs):** The company relies heavily on these for preclinical studies, clinical trials, and manufacturing, making their performance critical to development timelines and costs.
• **Creditors:** The 'going concern' doubt raises concerns about the company's ability to meet future obligations.

Next Steps

• Conduct additional analyses to further understand the results of the TTI-101 IPF Phase 2 clinical trial and inform next steps for the program.
• Report preliminary topline data from the TTI-101 Phase 1b/2 HCC clinical trial in the first half of 2026.
• Report topline data from the TTI-109 Phase 1 trial in healthy volunteers in the first half of 2026.
• Seek additional funding through equity offerings, debt financings, credit/loan facilities, and strategic alliances/licensing arrangements.
• Remediate identified material weaknesses in internal control over financial reporting by adding experienced personnel and formalizing control design and implementation.

Key Dates

Recommendation

The filing presents a highly concerning financial and operational picture. The primary clinical setback with the TTI-101 IPF Phase 2 trial failing to meet its goals is a major blow to the pipeline, especially given the high discontinuation rates due to adverse events. This raises questions about the broader STAT3 inhibitor platform's tolerability in non-oncology indications. Critically, management explicitly states 'substantial doubt about the Company's ability to continue as a going concern,' indicating severe liquidity issues despite a recent merger. The company has no revenue, continues to incur significant losses, and will require substantial additional capital, which is not assured. The identified material weaknesses in internal controls further compound the risk profile. While there are other pipeline candidates (TTI-101 HCC, TTI-109), their success is uncertain and far off. Given the immediate clinical failure, severe financial distress, and governance concerns, a seasoned investor would likely recommend a strong sell to mitigate further downside risk.

Keywords

Biopharmaceutical, STAT3 inhibitor, TTI-101, TTI-109, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Clinical-stage, Phase 2 trial, Drug development, SEC filing, 10-Q, Going concern, Merger, Clinical trial failure, Oncology, Fibrosis